Mandisa Singata-Madliki to Ritonavir
This is a "connection" page, showing publications Mandisa Singata-Madliki has written about Ritonavir.
Connection Strength
0,395
-
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life. Sci Rep. 2021 02 04; 11(1):3173.
Score: 0,178
-
Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding. Antimicrob Agents Chemother. 2017 02; 61(2).
Score: 0,135
-
Lopinavir-Ritonavir Impairs Adrenal Function in Infants. Clin Infect Dis. 2020 08 14; 71(4):1030-1039.
Score: 0,043
-
Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial. Lancet HIV. 2019 05; 6(5):e307-e314.
Score: 0,039